Investigation Report on China Sorafenib Market, 2010-2019
Description
The incidence of liver cancer and kidney cancer in China grows gradually. According to the Guidelines for Kidney Cancer Diagnosis and Treatment in China (the 2013 version), kidney cancer accounts for 2%-3% of adult malignant tumors in China and reports an obvious rise in incidence in recent years in China. Kidney cancer has surpassed bladder cancer to become the first in death related with urological tumors with its incidence growing at an average rate of 6.5% during the past two decades. According to the World Cancer Report 2014, China ranked first in the new cases of liver cancer and its death toll. Currently, liver cancer, with 0.257 in 1 million suffering from it, has become the third malignant tumor after stomach cancer and lung cancer in terms of mortality. As a novel small molecular multi-targeted inhibitor of tyrosine kinase, sorafenib is approved by FDA to treat unresectable advanced renal cell carcinoma and unresectable or metastasized primary hepatocellular carcinoma. Co-developed by Bayer and Onyx Pharmaceuticals, sorafenib got imported drug license in 2006 and was approved by China Food and Drug Administration to enter the market for the treatment of liver cancer in 2008.
According to CRI’s survey on 20 sample hospitals in key regions in China, sales value of sorafenib was CNY 147 million in 2013 and CNY 165 million in 2014, increasing 12.24% year on year.
With the degradation of environmental pollution and changes in lifestyle, the incidence of liver cancer keeps rising. Hence the vast demand for sorafenib in China. Currently, sorafenib in the Chinese market all come from Bayer AG i.e. Bayer enjoys a market share of 100%.
Readers can get at least the following information from this report:
The incidence of liver cancer and kidney cancer in China grows gradually. According to the Guidelines for Kidney Cancer Diagnosis and Treatment in China (the 2013 version), kidney cancer accounts for 2%-3% of adult malignant tumors in China and reports an obvious rise in incidence in recent years in China. Kidney cancer has surpassed bladder cancer to become the first in death related with urological tumors with its incidence growing at an average rate of 6.5% during the past two decades. According to the World Cancer Report 2014, China ranked first in the new cases of liver cancer and its death toll. Currently, liver cancer, with 0.257 in 1 million suffering from it, has become the third malignant tumor after stomach cancer and lung cancer in terms of mortality. As a novel small molecular multi-targeted inhibitor of tyrosine kinase, sorafenib is approved by FDA to treat unresectable advanced renal cell carcinoma and unresectable or metastasized primary hepatocellular carcinoma. Co-developed by Bayer and Onyx Pharmaceuticals, sorafenib got imported drug license in 2006 and was approved by China Food and Drug Administration to enter the market for the treatment of liver cancer in 2008.
According to CRI’s survey on 20 sample hospitals in key regions in China, sales value of sorafenib was CNY 147 million in 2013 and CNY 165 million in 2014, increasing 12.24% year on year.
With the degradation of environmental pollution and changes in lifestyle, the incidence of liver cancer keeps rising. Hence the vast demand for sorafenib in China. Currently, sorafenib in the Chinese market all come from Bayer AG i.e. Bayer enjoys a market share of 100%.
Readers can get at least the following information from this report:
- market size of sorafenib in China
- major manufacturers of sorafenib in Chinese market
- retail price of sorafenib in China
- market outlook of sorafenib in China
- manufacturers of anti-tumor drugs
- investors/ research institutions interested in Chinese medicine market
- any interest in the medicine market, please contact CRI for customized survey service
1 RELATED CONCEPTS OF SORAFENIB
1.1 Indication
1.2 Sales in Global Market
2 MARKET PROFILE OF SORAFENIB IN CHINA
2.1 Patent and Approval Information of Sorafenib in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF SORAFENIB IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF SORAFENIB IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF SORAFENIB IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF SORAFENIB IN CHINESE HOSPITALS IN 2014
Bayer Pharma AG (Trade Name: Nexavar)
7 MAJOR MANUFACTURERS OF SORAFENIB IN CHINESE MARKET, 2010-2014
8 OUTLOOK OF SORAFENIB MARKET IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Patent Status of Sorafenib in China
Chart Approval Information of Sorafenib in China
Chart Sales Status of Sorafenib in China
Chart Sales Value of Sorafenib in China, 2010-2014
Chart Sales Value of Sorafenib in Some Regions in China, 2010-2014
Chart Sales Volume of Sorafenib in China, 2010-2014
Chart Sales Volume of Sorafenib in Some Regions in China, 2010-2014
Chart Market Share of Sorafenib Manufacturers for Sales Value in China, 2010-2014
Chart Market Share of Sorafenib Manufacturers for Sales Volume in China, 2010-2014
Chart Sales Volume and Market Share of Bayer Pharma AG in China, 2010-2014
Chart Sales Value and Market Share of Sorafenib Tablets in China, 2010-2014
Chart Sales Volume and Market Share of Sorafenib Tablets in China, 2010-2014
Chart Price of Sorafenib Made by Bayer Pharma AG in Some Chinese Cities in 2014
1.1 Indication
1.2 Sales in Global Market
2 MARKET PROFILE OF SORAFENIB IN CHINA
2.1 Patent and Approval Information of Sorafenib in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF SORAFENIB IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF SORAFENIB IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF SORAFENIB IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF SORAFENIB IN CHINESE HOSPITALS IN 2014
Bayer Pharma AG (Trade Name: Nexavar)
7 MAJOR MANUFACTURERS OF SORAFENIB IN CHINESE MARKET, 2010-2014
8 OUTLOOK OF SORAFENIB MARKET IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Patent Status of Sorafenib in China
Chart Approval Information of Sorafenib in China
Chart Sales Status of Sorafenib in China
Chart Sales Value of Sorafenib in China, 2010-2014
Chart Sales Value of Sorafenib in Some Regions in China, 2010-2014
Chart Sales Volume of Sorafenib in China, 2010-2014
Chart Sales Volume of Sorafenib in Some Regions in China, 2010-2014
Chart Market Share of Sorafenib Manufacturers for Sales Value in China, 2010-2014
Chart Market Share of Sorafenib Manufacturers for Sales Volume in China, 2010-2014
Chart Sales Volume and Market Share of Bayer Pharma AG in China, 2010-2014
Chart Sales Value and Market Share of Sorafenib Tablets in China, 2010-2014
Chart Sales Volume and Market Share of Sorafenib Tablets in China, 2010-2014
Chart Price of Sorafenib Made by Bayer Pharma AG in Some Chinese Cities in 2014
